Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05790564 · ClinicalTrials.gov registry record · NA

Almonds to Improve Gut Health and Decrease Inflammation

A NA study of Inflammation and Metabolic Syndrome, sponsored by Oregon State University.

Active
Registry status
NA
Development phase
80
Enrollment target
1
Study location

NCT05790564: Active NA study of Inflammation and Metabolic Syndrome, sponsored by Oregon State University.

NCT05790564 is a NA study of Inflammation and Metabolic Syndrome that is active but no longer recruiting, run by Oregon State University. The registered enrollment target is 80 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05790564, a NA study of Inflammation and Metabolic Syndrome, is active but no longer recruiting, sponsored by Oregon State University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

Almonds are a good source of beneficial compounds. This study will investigate if eating almonds everyday for 12 weeks can affect gut health and inflammation in persons with metabolic syndrome. Investigators will measure changes in metabolism, heart health, and the levels of vitamins and other compounds from almonds.

Primary Outcome

Change from baseline at week 4: Marker of gut barrier function and health, serum endotoxin

Conditions Studied

Inflammation Metabolic Syndrome Dysbiosis

Interventions

  • OTHER Crackers
  • OTHER Almond

Study Locations (1)

Oregon

  • Oregon State University - Corvallis

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2022-11-17
Est. Completion 2025-07
Phase NA
Oregon State University

33 total trials

What the registry record for NCT05790564 still lists

NCT05790564 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (72% lower).

The record links to 3 conditions, with Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Crackers is the first listed.

NCT05790564 reports a single indexed study location in Oregon.

Frequently Asked Questions

What is clinical trial NCT05790564 about?

NCT05790564 is a clinical study titled "Almonds to Improve Gut Health and Decrease Inflammation". Almonds are a good source of beneficial compounds. This study will investigate if eating almonds everyday for 12 weeks can affect gut health and inflammation in persons with metabolic syndrome. Investigators will measure changes in metabolism, heart health, and the levels of vitamins and other compo...

What is the current status of trial NCT05790564?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2022-11-17. Estimated completion is 2025-07.

What conditions does trial NCT05790564 study?

This clinical trial studies the following conditions: Inflammation, Metabolic Syndrome, Dysbiosis.

What interventions are being tested in trial NCT05790564?

The interventions under investigation include: Crackers (OTHER), Almond (OTHER).

Who is sponsoring clinical trial NCT05790564?

This trial is sponsored by Oregon State University, which has 33 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05790564 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Inflammation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05790564's enrollment target sits among peer trials

80 52nd of 132 higher than 79 of 132 other Inflammation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05790564, the US trial registry maintained by the National Library of Medicine. NCT05790564 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.